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Vaccination is the most effective means of preventing infectious diseases. Despite the suc-
cess ofmany vaccines, there is presently little knowledge of the immunological mechanisms
that mediate their efficacy. Such information will be critical in the design of future vaccines
against old and new infectious diseases. Recent advances in immunology are beginning to
provide an intellectual framework with which to address fundamental questions about how
the innate immune system shapes adaptive immunity. In this review, we summarize current
knowledge about how the innate immune systemmodulates the quantity and quality of long-
term T and B cell memory and protective immune responses to pathogens. In addition, we
point out unanswered questions and identify critical challenges, the solution of which, we
believe, will greatly facilitate the rational design of novel vaccines against a multitude of
emerging infections.Introduction
A hallmark of the immune system is its ability to remember
an encounter with a pathogen for several decades, even
for a whole lifetime (Kaech et al., 2002). This fundamental
property of the immune system is the basis for vaccina-
tion, and the goal of a successful vaccine is to induce
long-term protective immunity against a given pathogen.
A central component of vaccines are immune stimulating
agents called adjuvants that enhance both the magnitude
and duration of immune responses. The nature of the
adjuvant can determine the particular type of immune re-
sponse, which may be skewed toward cytotoxic T cell
(CTL) responses, antibody responses, or particular clas-
ses of T helper (Th) responses and antibody isotypes (Pu-
lendran, 2004; Rappuoli, 2004). This is of vital importance
since effective protection against different pathogens re-
quires distinct types of immune responses. Despite the
common origins of vaccinology and immunology in the
pioneering work of Pasteur, Jenner, and others, most of
our best vaccines have been empirically derived (Plotkin,
2005; Rappuoli, 2004). Therefore, we are largely ignorant
of the immunological mechanisms by which our best vac-
cines work. Furthermore, themost commonly used empir-
ical adjuvants in clinical practice, alum and the oil-based
formulation MF59, while useful for enhancing antibody re-
sponses, have no discernible effect on the cellular immune
responses. However, recent advances in immunology
have triggered research into themechanisms that underlie
the innate and adaptive immune responses against path-
ogens and vaccines. This information will aid in the devel-opment of vaccines against pathogens such as HIV, TB,
malaria, and dengue, which have posed difficult chal-
lenges.
Emerging concepts in innate immunity suggest that
dendritic cells (DCs) play a critical role in sensing patho-
gens or vaccines, either directly or indirectly, and integrat-
ing this information to regulate the quantity, quality, and
longevity of the adaptive immune response (Janeway
and Medzhitov, 2002; Banchereau et al., 2000; Shortman
and Liu, 2002). In this review, we will discuss these ad-
vances in innate and adaptive immunity and their rele-
vance to vaccine development. This review is divided
into four parts. (1) The first part (Innate Immunity: The Sci-
ence of Adjuvants) examines how the innate immune sys-
tem ‘‘senses’’ pathogens and vaccines by recognizing
pathogen-associated molecular patterns (PAMPs) via
pathogen recognition receptors (PRRs) such as Toll-like
receptors (TLRs), which are expressed by DCs (Germain,
2004; Beutler, 2004; Janeway and Medzhitov, 2002;
Takeda et al., 2003). This section briefly summarizes the
biology of TLRs and other PRRs and then discusses the
immunological consequences of triggering distinct PRRs
on DCs. (2) The second section (Programming Adaptive
Immunity with Innate Immunity) discusses the critical pa-
rameters of T and B cell responses that are controlled
by the innate immune system. The goal of this section is
to explore the functional elements of innate immunity
and their roles in shaping the quantity and quality of T
and B cell memory (and thus protective immunity) and
identify fundamental gaps in our knowledge, whichCell 124, 849–863, February 24, 2006 ª2006 Elsevier Inc. 849
Figure 1. Triggering Distinct TLRs on DCs Elicits Different Cytokine Profiles and Different Immune Responses
Triggering DCs through TLRs 1–10 results in the induction of distinct DC responses and adaptive immunities. In humans, TLRs 9 and 7 are expressed
in the ER/phagolysosomes of plasmacytoid DCs, and triggering these yields robust IFN-a, which subsequently biases toward Th1 responses and also
favors crosspresentation, CD8+ T cell priming, and CTLs. Human myeloid DCs express TLR2 (heterodimerized with TLRs 1 or 6); TLR3 (in ER/phag-
olysosomes); and TLRs 4, 5, 8, and 11 on the surface. Stimulation of TLRs 3, 4, 5, or 8 is known to yield robust IL-12p70 and potent Th1 responses.
Stimulation of TLRs 3 or 4 is also known to yield some IFN-a and favor crosspresentation and CD8+ T cell priming. However, stimulation of TLR2 can
often yield a response characterized by little IL-12p70, robust IL-10, and a bias toward Th2 or T regulatory responses. Interestingly, the TLRs asso-
ciated with different adaptor proteins, which mediate distinct functions. For example, MyD88 signaling mainly yields proinflammatory cytokines (IL-
12, IL-6, and TNF). Signaling via TRIF or TRAM induces robust type 1 interferons and upregulates costimulatory molecules.represent critical challenges for the future. (3) The third
part (Learning Immunology from ‘‘Good’’ Vaccines)
discusses the merits of studying empirically derived,
‘‘successful’’ vaccines such as the yellow fever vaccine
(YF-17D) to unravel the innate immune receptors and im-
munological mechanisms by which they mediate protec-
tion, with a view to exploiting this knowledge in the design
of future vaccines. (4) In the final section (SomeCritical Im-
munological Challenges for Vaccinologists), we conclude
by briefly summarizing the critical challenges discussed in
the preceding sections that could guide the translation of
innate immunity to vaccine-induced protective immunity.
Innate Immunity: The Science of Adjuvants
Although adjuvants have long been known to shape the
quality and quantity of immune responses, it is only re-
cently that the mechanisms of their action are beginning
to be revealed. A key event that triggers the immune re-
sponse is when the immune system ‘‘senses’’ the vaccine
or microbe. Information sensed about the vaccine or
microbe is integrated by DCs and translated to antigen-
specific T and B cells to modulate the strength, quality,
and persistence of the adaptive immune response.850 Cell 124, 849–863, February 24, 2006 ª2006 Elsevier Inc.Direct Innate Immune Sensing
Since the review by Akira and colleagues in this issue of
Cell (Akira et al., 2006) provides a detailed account of
this topic, wewill only discuss it briefly here. The innate im-
mune system can recognize microbes directly through
various PRRs expressed in, and on, DCs. An important
family of PRRs are the TLRs (Germain, 2004; Beutler,
2004; Janeway and Medzhitov, 2002; Takeda et al., 2003),
which are widely expressed on innate immune cells, in-
cluding DCs,macrophages, mast cells, neutrophils, endo-
thelial cells, and fibroblasts. TLRs have broad specificity
for conserved molecular patterns shared by bacteria, vi-
ruses, and parasites (Figure 1). Moreover, different TLRs
are expressed by distinct subpopulations of DCs and in
distinct cellular compartments. TLR4, for example, is ex-
pressed on the surface membrane of human myeloid
DCs and monocytes and is essential for the recognition
of LPS (Beutler, 2004). In contrast, TLR9 appears to be ex-
pressed in the endosomal compartment of plasmacytoid
DCs (pDCs) and B cells and is involved in the recognition
of viral and intracellular bacterial DNA (Takeda et al.,
2003). Signaling via TLRs on innate immune cells often
represents the trigger for an adaptive immune response.
Although much research has focused on the TLR family
as innate sensing receptors, emerging evidence also
points to other families of plasma-membrane and cyto-
plasmic receptors, including the C type lectins and NOD
proteins (see Akira et al., 2006, Geijtenbeek et al., 2004; In-
ohara et al., 2005). The C type lectins such as DC-SIGN
recognize a range of microbial stimuli from pathogens
such as HIV, HCV, Helicobacter pylori, and Mycobacte-
rium tuberculosis. NOD proteins recognize components
of intracellular bacteria. Interestingly, mutations in the
gene encoding NOD2 have been associated with in-
creased frequencies of inflammatory bowel disease, sug-
gesting a role for these proteins in regulating inflammation
(Inohara et al., 2005). In the case of viruses, in addition to
TLR-dependent recognition, viral nucleic acids can also
signal through TLR-independent mechanisms. For exam-
ple, RIG-I and melanoma differentiation-associated gene
5 (Mda5; also called helicard), both intracellular RNA heli-
cases, can sense dsRNA (for more information, see Akira
et al., 2006).
PRRs and DC Subsets
The adaptive immune system has evolved diverse re-
sponses to defend the host against a myriad of different
pathogens. For example, immune responses are diverse
with respect to the cytokines made by Th cells and the
class of antibodies secreted by B cells. Thus, in response
to intracellular microbes or viruses, CD4+ Th cells differen-
tiate into Th1 cells, which produce IFN-g and help the in-
duction of CD8+ cytotoxic T cells (CTLs), which kill the
cells infected with the intracellular pathogens; in contrast,
helminths induce the differentiation of Th2 cells, whose
cytokines (principally IL-4, IL-5, and IL-10) induce IgE
and eosinophil-mediated destruction of the pathogens
(O’Garra and Robinson, 2004; Mowen and Glimcher,
2004). Furthermore, so-called T regulatory cells that sup-
press the proliferation and differentiation of Th or cytotoxic
T cells serve to limit the potential immunopathology that
might be caused by an overexuberant immune response.
Interestingly, specific pathogens have evolved mecha-
nisms to induce T regulatory cells, most likely as an im-
mune evasion strategy to suppress host immunity
(O’Garra and Vieira, 2004). How does the immune system
generate such a diversity of responses? The existence of
multiple subsets of DCs raises the question of whether
they are functionally specialized to promote distinct im-
mune responses (Pulendran, 2004, 2005; Shortman and
Liu, 2002). In mice, for example, the splenic CD8a+ versus
CD8a– DCs can differentially influence the Th1/Th2 bal-
ance (Pulendran et al., 1999; Maldonado-Lopez, 1999).
Furthermore, plasmacytoid DCs in humans andmice pref-
erentially produce IFN-a (reviewed by Liu, 2005). In part,
such functional specialization seems to be achieved by
the differential distribution of TLRs on distinct DC sub-
sets—for example, in humans, TLR9 and TLR7, which
mediate robust induction of type I IFNs, are preferentially
expressed on plasmacytoid DCs (Figure 1). However, de-
spite these examples of functional specializations, DC
subsets also exhibit considerable functional plasticity.CThus, activation of a given DC subset via distinct PRRs
can differentially program that subset to stimulate distinct
types of T cell responses (Pulendran, 2004, 2005).
Indirect Innate Immune Sensing
DCs can also sense pathogens indirectly by detecting in-
flammatory mediators produced by various cells such as
macrophages, NK cells, NK T cells, mast cells, and endo-
thelial cells (Germain, 2004; Beutler, 2004; Janeway and
Medzhitov, 2002; Takeda et al., 2003). Such ‘‘danger sig-
nals’’ (Matzinger, 1994) include heat-shock proteins (Sri-
vastava, 2002) and uric-acid crystals (Shi et al., 2003).
Therefore, DCs are equipped with multiple surveillance
mechanisms that can sense pathogens either directly or
indirectly and thus represent an important nodal point in
which pathogen- or vaccine-associated signals are inte-
grated and transmitted to the adaptive immune system.
Programming Adaptive Immunity
with Innate Immunity
Despite the paucity of information on the correlates of
protective immunity against pandemics like HIV, TB, and
malaria, growing evidence suggests that prophylactic
vaccines against such diseases must be capable of stim-
ulating (1) long-lived, antigen-specific plasma cells that
produce neutralizing antibody; (2) persisting CD4+ and
CD8+ T cells; and (3) migration of pathogen-specific T
and B cells to mucosal sites. Exactly what parameters of
innate immune activation regulate (1)–(3) is still largely
a mystery and will be considered below.
T Cell Immunity: Programming Memory T Cell
Generation and Maintenance
Adaptive immune responses are initiated in the T cell-rich
areas of the secondary lymphoid organs, where naive T
cells encounter antigen-bearing DCs that have migrated
there from the site of vaccination. Before vaccination, an-
tigen-specific T cells are present in the host at very low fre-
quencies (Kaech et al., 2002). After vaccination, these
‘‘naive’’ T cells expand (‘‘clonal expansion’’ phase, 7–10
days) to reach a markedly higher frequency (as much as
100,000-fold higher, in the case of antigen-specific CD8+
T cells responding to many viruses; Murali-Krishna et al.,
1998; Butz and Bevan, 1998). Such proliferating cells dif-
ferentiate into effector T helper cells or cytotoxic T lym-
phocytes.
After removal of the antigen, there is a phase of numer-
ical reduction of antigen-specific cells (‘‘clonal contrac-
tion’’ phase, 2–4 weeks) whereby a subset of effector T
cells survive and further differentiate into long-lasting
memory T cells whose numbers are maintained over time
(‘‘maintenanceofmemory’’ phase) (Kaechet al., 2002).De-
spite the fact that these three phases have been studied in
some detail, the question of whether they occur in different
microenvironments has not been thoroughly explored.
This is in contrast to the situationwithB cells, wheremicro-
environments like germinal centers and plasma foci repre-
sent the sites where somatic hypermutation of immuno-
globulin genes in developing memory B cells and the
generation of short-lived antibody-forming cells occur,ell 124, 849–863, February 24, 2006 ª2006 Elsevier Inc. 851
Figure 2. Innate Variations on a Theme of Memory
Multiple ways in which the innate immune system might modulate the clonal expansion, clonal contraction, and maintenance of memory during an
antigen-specific T cell response.respectively (Ahmed and Gray, 1996; McHeyzer-Williams
and McHeyzer-Williams, 2005). With T cells also, it is pos-
sible that clonal expansion, clonal contraction, and mem-
ory-cell maintenance occur in specialized microenviron-
ments under the control of innate immune mechanisms.
Enhancing the Quantity of Memory T Cells. It may be
safely assumed that increased numbers of memory T cells
result in enhanced protection against a pathogen, al-
though there might be a threshold number of memory
T cells above which no further benefits for protection are
evident. In principle, the quantity of memory T cells might852 Cell 124, 849–863, February 24, 2006 ª2006 Elsevier Inc.be regulated by (1) enhancing the expansion phase, (2)
reducing the contraction phase, (3) stabilizing the mem-
ory phase, or (4) some combination of these strategies
(Figure 2).
Enhancing Clonal Expansion. Accelerating the genera-
tion of effector CD8+ T cells by vaccination may be crucial
to control pathogens that cause rapid disease and mor-
bidity, including biothreat agents like Bacillus anthracis
and Yersinia pestis. The rate of T cell expansion is a func-
tion of the number of naive T cells recruited into the
response, the rate of T cell proliferation, and the rate of
cell death. These, in turn, are dependent on the ‘‘context’’
in which the T cell recognizes antigen, the abundance of
antigen, and the duration of antigen exposure during the
expansion phase, all of which can be regulated by innate
immune mechanisms.
Within the T cell-rich areas of the lymphoid organs,
antigen-bearing DCs and the rare, antigen-specific naive
T cells must find each other. Recent estimates suggest
that the precursor frequency of naive epitope-specific
CD8 T cells is on the order of 1 in 2  105. Thus, in an un-
infected mouse containing 2–4  107 naive CD8 T cells,
there are estimated to be 100–200 epitope-specific cells
(Blattman et al., 2002). Therefore, in any given draining
lymph node, this is likely to be considerably smaller—per-
haps only 10 or 20. Finding one of those T cells in a lymph
node may thus seem challenging, especially if DCs have
a relatively short half-life. In the apparent absence of mi-
crobial stimulation, the rate of migration of tissue DCs
into the draining lymph nodes occurs constitutively but
at a relatively low level. Such DCs have engulfed dead
host cells and present ‘‘self-antigens’’ to naive T cells so
as to establish and maintain peripheral tolerance to self
(Hawiger et al., 2001). However, in response to signals
from pathogens or adjuvants (e.g., TLR ligands), resident
immature DCs at the site of infection or vaccination un-
dergo a maturation program characterized by enhanced
expression of costimulatory molecules and inflammatory
cytokines andmigrate to the draining lymph nodes. The in-
creased cytokine and chemokine levels at the site of infec-
tion also result in the recruitment of monocytes and DC
precursors from the blood. When such precursors enter
the site of infection, they rapidly differentiate into DCs
and replenish the depletion of DCs from that site (Ban-
chereau et al., 2000; Shortman and Liu, 2002). The precise
roles of distinct DC subsets such as Langerhans cells,
dermal DCs, and plasmacytoid DCs in this process are
largely unknown. Recent work, however, suggests the
concerted action of resident DC subsets and DCs that mi-
grate from the periphery in serial waves (Itano et al., 2003),
each of which are specialized to perform distinct functions
such as ferrying the antigen to the site, crosspresentation
to CD8+ T cells, IL-12 secretion, and IFN-a secretion. Un-
der these inflammatory conditions, the T cell areas of the
draining lymph nodes receive large numbers of highly
stimulatory DCs. This influx results in an increased density
of antigen-MHC complexes, costimulatory molecules,
and proinflammatory cytokines. Furthermore, mature
DCs extend many long dendrites, which can cover a con-
siderable volume, thus enhancing the potential zone of
DC-T cell contacts, as demonstrated by elegant studies
using two-photon laser scanning microscopy (Miller
et al., 2002). It has also been suggested that the chemo-
kines secreted by activated DCs such as thymus and ac-
tivation-regulated cytokine (TARC) or macrophage-de-
rived chemokine (MDC) attract antigen-specific T cells
(Tang and Cyster, 1999; Lanzavecchia and Sallusto,
2001), although this is yet to be clearly demonstrated
in vivo by live-tissue imaging studies (Huang et al., 2004).Once the DC has located the antigen-specific T cell and
recruited others to the vicinity, several events facilitate
productive T cell activation. In vitro studies suggest that
at the site of cell-cell contact, the ‘‘immunological syn-
apse,’’ proteins segregate into two concentric areas:
(1) a central area known as c-SMAC (central supramolec-
ular activation cluster), where the TCR-MHC and addi-
tional short molecules such as CD2, CD28, protein kinase
C-q (PKC-q), Lck, Fyn, CD4, and CD8 cluster, and (2) a
peripheral outer ring known as p-SMAC, containing larger
molecules such as LFA-1 and CD45, which strengthen the
synapse (reviewed by Bromley et al., 2001). Although
c-SMAC formation does not appear to be critical to initiate
TCR signaling, it is believed that c-SMACs enhance T cell
activation by concentrating the TCR and MHC in a single
area for sustained periods, thus facilitating a ‘‘serial trig-
gering’’ mechanism, allowing one MHC-peptide complex
to trigger repeatedly through as many as 200 TCR mole-
cules (Lanzavecchia and Sallusto, 2001). Thus, differ-
ences in timing, spacing, andmolecular composition of the
synapse can strongly influence the magnitude of the T cell
response. An important challenge is to determine whether
c-SMAC and p-SMAC structures observed in vitro actu-
ally form in vivo. In this context, recent in vivo imaging
studies with two-photon microscopy suggest that, for
CD8+ T cells, interactions with DCs occur in three succes-
sive stages: (1) transient serial encounters during the first
8 hr, in which the T cells progressively decrease their
motility and upregulate activation markers; (2) long-lasting
(>1 hr) stable conjugates with DCs during the next 12 hr, in
which the T cells begin to secrete interleukin-2 and inter-
feron-g; and (3) T cell migration on the second day, coin-
ciding with the onset of proliferation and reduction of DC
contacts (Mempel et al., 2004). Consistent with these
kinetics, T cells appear to be able to commit to clonal ex-
pansion after less than 24 hr of antigenic stimulation. CD8+
T cells especially appear to begin a program of cell differ-
entiation and proliferation within hours of exposure of the
‘‘parental’’ cell to antigenic stimulus that results in 7–10
cell divisions over the course of the next few days (Kaech
and Ahmed, 2001; van Stipdonk et al., 2001; Mercado
et al., 2000).
Once synapse formation is underway, commitment of
T cells to clonal expansion can be regulated by the
strength and duration of TCR signaling, which is depen-
dent on the context in which the T cell sees the anti-
gen—for instance, the subset of DCs, the density of pep-
tide-MHC complexes on the surface of DCs, the duration
of DC-T cell interactions, and the life span of DCs (Lanza-
vecchia and Sallusto, 2001). For example, the induction of
the prosurvival molecule bcl-XL in DCs is known to aug-
ment immune responses (Josien et al., 2000). Further-
more, specific molecules expressed on the surface of
DCs (so-called costimulatory molecules) can provide ad-
ditional signals that augment the interaction of TCR with
MHC-peptide complexes. For example, molecules of the
B7 family such as CD80 and CD86, which are expressed
on DCs, bind to their receptor CD28 on T cells and resultCell 124, 849–863, February 24, 2006 ª2006 Elsevier Inc. 853
in the upregulation of CD40 ligand on T cells. In turn, CD40
ligand binds to CD40 on DCs and ‘‘licenses’’ the DCs to
express additional molecules that influence T cell differen-
tiation. Such molecules include cytokines such as IL-12
and IL-18, which are secreted by DCs and induce IFN-g
production by T cells, thus favoring robust Th1 immunity
(Lanzavecchia and Sallusto, 2001). In addition, cytokines
such as IFN-a secreted by pDCs (Liu, 2005), or proinflam-
matory cytokines such as TNF-a or IL-6, may act by en-
hancing costimulatory molecules and immunogenicity of
DCs themselves (Le Bon et al., 2003); theymay also act di-
rectly on T cells to induce robust CD8+ T cell expansion
(Kolumam et al., 2005) or bypass suppressor effects of T
regulatory cells (Pasare andMedzhitov, 2003). Thus, adju-
vants that enhance DC survival, induction of costimulatory
molecules, and controlled release of type I IFNs and proin-
flammatory cytokines may be particularly effective in in-
ducing T cell expansion. However, these factors must be
strictly regulated since prolonged antigenic stimulation
(Zajac et al., 1998; Moskophidis et al., 1993), chronic stim-
ulation with DCs (Menges et al., 2001), or inappropriate
timing of exposure to IFN-a (Nagai et al., 2003) can impair
T cell differentiation.
In addition, signals from other innate immune cells, such
asNK or NK T cells, can also influence clonal expansion. In
contrast to conventional T cells that recognize peptide an-
tigens, NK T cells recognize glycolipids via the CD1d re-
ceptor. Activation of NK T cells in mice by injection of
a-GalCer, a glycolipid ligand for CD1d, induces rapid re-
lease of cytokines and stimulates activation of NK cells,
DCs, and T cells. Immune responses to injection of
a-GalCer-loaded mature DCs in patients with advanced
cancers resulted in a more than 100-fold increase in ex-
pansion of several subsets of NK T cells for up to 6months
after vaccination. NK T activation was associated with an
increase in serum levels of IL-12 p40 and IP-10, factors as-
sociated with robust Th1 responses. In addition, there was
an increase in memory CD8+ T cells specific for cytomeg-
alovirus in vivo in response to a-GalCer-loaded DCs
(Chang et al., 2005). Furthermore, recent evidence
suggests that NK cell-secreted IFN-g augments Th1 re-
sponses and that this occurs via TLR signaling (Martin-
Fontecha et al., 2004).
Reducing Clonal Contraction. Emerging evidence sug-
gests that clonal contraction can also be influenced by
several cell-extrinsic factors, such as the cytokine envi-
ronment, costimulatory molecules, and the strength and
duration of signaling by antigen-bearing DCs. With re-
spect to cytokines, type I IFNs, as well as members of
the IL-2 family (e.g., IL-2, IL-4, IL-7, and IL-15, which
share a common g chain receptor), can enhance T cell
survival (Marrack and Kappler, 2004). Consistent with
this, newly emerging memory CD8+ T cells express IL-
7R (Kaech et al., 2003). In addition to such cytokines, cer-
tain costimulatory molecules can regulate cell death. For
example, mice deficient in CD40 ligand display enhanced
death of CD8+ T cells and 10-fold lessened memory-cell
formation after viral infection, but the clonal expansion854 Cell 124, 849–863, February 24, 2006 ª2006 Elsevier Inc.phase appears to be normal (Whitmire and Ahmed,
2000).
Stabilizing the Memory Phase. In the case of CD8+ T
cells, the memory phase seems relatively stable, suggest-
ing that the rate of cell death is equal to the rate of cell
division, known as ‘‘homeostatic proliferation,’’ which ap-
pears to operate in the absence of antigenic stimulation
(Murali-Krishna et al., 1999). However, with CD4+ T cells,
there appears to be a decline in antigen-specific memory
T cells after an initial immune response to lymphocytic
choriomeningitis virus (LCMV) in mice (Homann et al.,
2001). On the other hand, the numbers seem more stable
in humans vaccinated against smallpox (Hammarlund
et al., 2003). Clearly, factors that enhance cell division or
reduce cell death are important in maintaining the num-
bers of memory T cells. Cytokines such as IL-15, IL-7,
and thymic stromal lymphopoietin (TSLP) may be impor-
tant in both processes (Soumelis et al., 2002). For exam-
ple, memory CD8+ cells in bone marrow undergo more
vigorous homeostatic proliferation and respond faster to
antigen stimulation than those in other tissues (Di Rosa
and Santoni, 2002; Becker et al., 2005). Whether such cy-
tokines are constitutively produced by specific cell types
in the bone marrow is not known. Furthermore, similar to
in recent studies with memory B cells (McHeyzer-Williams
and McHeyzer-Williams, 2005), certain subsets of T cells
express TLRs (Peng et al., 2005). Although expression of
such molecules in memory T cells deserves further study,
it is an intriguing concept that continuous TLR signaling in
response to low levels of microbial stimuli might affect ho-
meostatic proliferation. As will be appreciated from the
above discussion, an important challenge is the elucida-
tion of mechanisms by which innate immunity and adju-
vants regulate memory T cell generation and maintenance
(critical challenge 1).
A counterpoint to understanding the influence of innate
immunity in memory T cell generation is to appreciate how
several pathogens, particularly those that cause chronic
infections such as HIV, HCV, and TB, can interfere with
this process to induce dysfunctional T cells. In this con-
text, our recent data suggest that, in mice chronically in-
fected with LCMV clone 13, antigen-specific CD8+ T cells
express very high levels of PD-1, a ligand for PD-L1 (Bar-
ber et al., 2006), another member of the B7 family, which,
unlike CD80 and CD86 discussed above, is known to be
an inhibitory receptor for T cells (Greenwald et al., 2005).
Interestingly, blockade of PD-L1/PD-1 interaction in vivo
with an antagonistic antibody relieves the inhibitory effect,
restores T cell function, and reduces viral load (Barber
et al., 2006).
Modulating the Quality of Effector and Memory T Cells
with Innate Immunity. As discussed above, a hallmark of
adaptive immunity is the existence of qualitatively different
types of responses, such as Th1, Th2, and T regulatory re-
sponses (O’Garra and Robinson, 2004; Mowen and
Glimcher, 2004; O’Garra and Vieira, 2004). In addition,
differentiatingmemory CD4+ and CD8+ T cells can be sub-
divided into the central memory and effector memory
Figure 3. Dendritic-Cell Signaling Path-
ways that Induce Th2 or T Regulatory
Responses, and Possible Strategies to
Overcome Such Pathways
Activation of the p38 and JNK MAPKs in DCs
mediates robust IL-12p70 and Th1 responses.
However, activation of the ERKMAPK results in
IL-10 production and impairment of IL-12p70 in
part via the AP-1 transcription factor c-Fos,
a repressor of IL-12 (Dillon et al., 2004; 2006).
Since IL-10 is known to exert potent regulatory
influences on DCs and T cells, it is conceivable
that such pathways might operate in DCs in
chronic infections or tumors. Thus, vaccination
strategies that encompass inhibitors of the
ERK/c-Fos pathway together with TLR ligands
might serve to ‘‘ease the regulatory brakes’’
while ‘‘stepping on the accelerator’’ via TLR ac-
tivation. Such strategies might include nano-
particles into which inhibitors of the ERK/c-
Fos pathway or other regulatory proteins such
as STAT3 or SOCS1 are encapsulated, to-
gether with the relevant antigen and multiple
TLR ligands.subsets, which differ in their phenotype, function, and
homing properties (Sallusto et al., 2004). A central prob-
lem is how the innate immune system regulates the gener-
ation of qualitatively distinct types of adaptive immune re-
sponses. This is considered below.
Innate Immune Control of T Helper Differentiation. Sev-
eral studies suggest that distinct subsets of DCs differen-
tially modulate T helper responses (Maldonado-Lopez,
1999; Pulendran et al., 1999; Rissoan et al., 1999).
However, the nature of the microbial stimulus and local
microenvironmental cues (Shortman and Liu, 2002; Pulen-
dran, 2005) also play important roles in tuning the T helper
response. For example, viruses stimulate IFN-a-mediated
differentiation of plasmacytoid DCs into Th1-inducing DCs
(Liu, 2005), whereas IL-3 induces such DCs to differentiate
into Th2-inducing DCs (Rissoan et al., 1999). Different
forms of the fungus Candida albicans instruct DCs to in-
duce either Th1 or Th2 responses, and E.coli LPS induces
IL-12(p70) in DCs, which elicits Th1 responses, while
P. gingivalis LPS, schistosome egg antigens (SEA), filarial
nematode-secreted products, or cholera toxin fail to
induce IL-12(p70) and stimulate Th2-like responses (re-
viewed in Pulendran, 2005). The cytokines and chemo-
kines in the local microenvironment can also modulate
DC function and immune responses. For example, Peyer’s
patch or respiratory-tract DCs prime Th2 responses, while
total spleen DCs prime Th1/Th0 responses (Iwasaki and
Kelsall, 2001). Furthermore, human epithelial cells trigger
DC-mediated allergic inflammation by producing TSLP
(Soumelis et al., 2002). These results are consistent with
observations that DCs in distinct microenvironments in-
duce different Th responses.
The nature of the PRRs that modulate DC cytokines and
the ensuing immune response is an area of active study.
Most TLRs induce strong IL-12(p70) fromDCs, which sub-sequently stimulate Th1 responses (Brightbill et al., 1999).
However, only a subset of the TLRs (TLRs 3, 4, 7, and 9)
can induce type 1 interferons, which are important for an-
tiviral defense (Liu, 2005). Emerging evidence suggests
that TLR2 ligands can stimulate Th2 or T regulatory re-
sponses (Agrawal et al., 2003b; Dillon et al., 2004, 2006;
Redecke et al., 2004). Themolecular mechanism by which
specific TLR2 ligands favor a Th2 bias remains to be es-
tablished, although recent work suggests that the robust
and sustained phosphorylation of ERKMAP kinase results
in phosphorylation of the AP-1 transcription factor c-Fos
in DCs, which in turn suppresses expression of the Th1-
defining cytokine IL-12, thus favoring a Th2 bias (Agrawal
et al., 2003b; Dillon et al., 2004) (Figure 3).
In thecaseof tolerogenic Tcell responses, the yeast cell-
wall particle zymosan, which consists of several carbohy-
drates, signals through both TLR2 and the C type lectin
dectin-1 and activates DCs to secrete the anti-inflamma-
tory cytokine IL-10 via a mechanism dependent on the
induction of ERKMAPkinase. Zymosan also inducesmac-
rophages in the splenic red pulp to secrete TGF-b, another
anti-inflammatory cytokine (Dillon et al., 2006). Consistent
with these effects on antigen-presenting cells (APCs), in-
jection of zymosan plus antigen into mice results in sup-
pression of the T cell response via a mechanism depen-
dent on IL-10 and TGF-b (Dillon et al., 2006). These data
suggest several targets for pharmacological modulation
of immune responses in various clinical settings (Figure 3).
It is conceivable that such regulatory innate immune net-
works are induced by pathogens that cause chronic infec-
tions or by tumors and result in induction of T regulatory
cells and suppression of immunity against the pathogens
or tumors (Figure 3) (O’Garra andVieira, 2004). Thus, an at-
tractive therapeutic strategy might be to inhibit regulatory
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adjuvant signals that enhance the immune response. For
example, such a strategy might consist of vaccine nano-
particles containing inhibitors of the ERK/c-Fos pathway
together with specific combinations of TLR ligands or in-
hibitors of other molecules such as the Janus kinase
STAT3 (Nefedova et al., 2004) or suppressor cytokine sig-
naling 1 (SOCS1) (Shen et al., 2004), which have also been
shown to exert regulatory functions in DCs (Figure 3). Such
strategies may well simultaneously release the ‘‘intrinsic
breaks’’ associatedwith chronic infections or tumorswhile
providing strong stimulatory signals via the TLR ligands.
Thus, elucidation of the signaling networks within DCs
that regulate Th2 or T regulatory responses and discovery
of strategies to relieve such regulatory pathways are
needed (critical challenge 2).
Innate Immune Control of Central Memory versus Effec-
tor Memory Differentiation. Central memory (TCM) cells
express CD62L and CCR7, reside in the T cell areas of
lymphoid organs, and respond to antigenic restimulation
by proliferating and rapidly differentiating into effector
cells. In contrast, effector memory (TEM) cells do not ex-
press CD62L and CCR7 but express receptors for migra-
tion into inflamed tissues and display immediate effector
functions (Sallusto et al., 2004). Based on these observa-
tions, a model was proposed in which tissue-homing
CCR7-negative effector memory cells serve a sentinel
role in the rapid control of invading pathogens. In contrast,
the lymph-node-homing CCR7-positive central memory
cells would be available in secondary lymphoid organs
as a reserve pool of memory cells fromwhich effector cells
can develop in case of a future infection (Sallusto et al.,
2004). Although this concept was based on data gener-
ated in vitro, recent in vivo studies suggest that antigen-
specific memory T cells persist in nonlymphoid com-
partments long after vaccination (Masopust et al., 2001),
which suggests that memory cells are indeed capable of
homing to such sites in vivo. Consistent with this, recent
studies suggest that CCR7 is required for T cell exit from
peripheral tissues (Debes et al., 2005). Clearly, an impor-
tant question is whether innate immune signals regulate
the differentiation of central versus effectormemory T cells
and, if so, what such signals are. Again, as with effector
cells, cytokines and the strength and duration of antigenic
stimulation appear to play important roles (Manjunath
et al., 2001). Recent studies suggest that central memory
T cells proliferate in response to IL-2, IL-7, and IL-15 and
differentiate into effector T cells (Sallusto et al., 2004). In
addition, the strength of the TCR signaling may influence
the decision to form central versus effector memory cells
(Gett et al., 2003). For example, during the early stages
of an immune response, the mass influx of highly stimula-
tory DCs might deliver strong TCR signals, thus favoring
effector T cell differentiation; however, at a later stage,
when the influx of highly stimulatory DCs begins to dimin-
ish, a milder form of T cell stimulation may favor the gener-
ation of central memory T cells. An alternative view is that
distinct subsets of DCs or different TLR ligandsmay differ-
entially induce central versus effector memory cells.856 Cell 124, 849–863, February 24, 2006 ª2006 Elsevier Inc.Innate Immune Control of Migration Patterns of Effector
T Cells. There is emerging evidence that T cells with dis-
tinct phenotypes can home to different tissues (Sallusto
et al., 2004). For example, expression of the gut-homing
receptors, namely the integrin a4b7 and the chemokine re-
ceptor CCR9, is essential for preferential homing to the gut
(Hamann et al., 1994; Kantele et al., 1999; Zabel et al.,
1999; Svensson et al., 2002). Retinoic acid enhances the
expression of a4b7 and CCR9 on T cells and imprints
themwith a gut tropism (Iwata et al., 2004). Since many in-
fections occur via mucosal transmission, a protective
CD8+ T cell-based vaccine must elicit memory CD8+ T
cells that either are present at the sites of virus entry prior
to infection or can promptly migrate to these sites after in-
fection. The expression of mucosal homing receptors is
likely to be a key factor in determining the homing behavior
of these cells in the genital and rectal mucosae. It was re-
cently shown that the expression of a4b7 integrin predicts
the rapid localization of adoptively transferred antigen-
specific CD8+ T cells to mucosal sites (Masopust et al.,
2004).Whereas the a4b7-negative TEMcells migrate pref-
erentially to the spleen, the a4b7+ TEMcells are capable of
migrating to the mucosal effector tissues (Masopust et al.,
2004). It is important to note that these a4b7-positive
effector CD8+ T cells lose a4b7 expression upon their ar-
rival in the mucosa, where they can survive for long pe-
riods of time (up to 1 year). This long-term persistence is
associated with high levels of bcl-2 expression and thus
appears to be related to long survival rather than to in
situ proliferation (Grayson et al., 2000). Thus, experiments
that assess the ability of adjuvants to induce prompt
migration of antigen-specific CD8+ T cells to mucosal
tissues represent a key area for future research (critical
challenge 1).
B Cell Immunity: Programming B Cell Differentiation
and Antibody Formation
Preexisting antibodies in the circulation and at themucosa
provide the first line of defense against reinfection by ex-
tracellular as well as intracellular pathogens. The differen-
tiation of B cells to antibody-producing plasma cells can
occur via three distinct pathways. The first two pathways
consist of very rapid IgM and IgA antibody production to T
cell-independent antigens, and the third is involved in
slower IgG antibody production, affinity maturation, and
memory B cell formation to T cell-dependent antigens
(Figure 4). These are considered below.
Programming B-1 B Cells to Rapidly Generate Neutral-
izing Antibodies and Shape ‘‘Natural Memory.’’ B-1 B cells
are primarily found in the peritoneal and pleural cavities
but also occur less frequently in the spleen and lymph no-
des and differ from conventional (follicular) B cells with
respect to localization, phenotype, activation status, and
antibody V gene usage (Baumgarth et al., 2005). They
appear to differentiate, even in the apparent absence of
antigenic stimulation, to produce IgM and IgA or ‘‘natural’’
antibodies (Baumgarth et al., 2005). Such B-1 B cells are
also involved in the initial IgM response to T cell-indepen-
dent antigens. Even though their V gene repertoire is
Figure 4. Programming B Cell Responses with Innate Immunity
(A) B-1 B cells are primarily found in the gut and pleural cavities and appear to differentiate even in the apparent absence of antigenic stimulation to
produce IgM and IgA ‘‘natural antibodies.’’
(B) Marginal-zone B cells are strategically located in the marginal zone of the spleen, where they play a dominant role in the early IgM response to
blood-borne pathogens. Recent studies suggest that immature DCs capture and transport bacteria to the spleen, provide survival signals in the
form of BAFF to marginal-zone B cells, and induce their differentiation to plasma cells. Both B-1 B cells (A) and marginal-zone B cells (B) appear
to exist in a persistent state of activation. This property might be exploited to generate persistent levels of broadly reactive neutralizing IgM and
IgA antibodies reactive to pathogens such as HIV. This might be accomplished using conjugate prophylactic vaccines comprised of the appropriate
TLR ligands conjugated with the specific antigens (e.g., HIV gp120) and administered (orally or intravenously) periodically to target the B-1 B cells or
marginal zone B cells and to induce persistent antibodies against pathogens.
(C) T cell-dependent B cell responses begin in the T cell-rich areas of the lymphoid organs, where DCs present antigen to antigen-specific T cells in the
context of MHC and costimulatory molecules such as the B7 molecules. The activated T cells then migrate to the border of the T cell area and B cell
follicles. Similarly, antigen-specific B cells in the B cell follicles that have ‘‘seen’’ antigen and perhaps received TLR stimulation also migrate to the
border of the T cell area and B cell follicles. Here, interactions between the antigen-specific T and B cells results in a B cell differentiation program
characterized by the formation of specialized microenvironments called germinal centers. Germinal centers are the sites of somatic hypermutation of
the immunoglobulin genes of the B cell receptors and the subsequent selection of high-affinity mutants by competition for antigen-antibody com-
plexes on the follicular dendritic cells (FDCs). The germinal center ‘‘reaction’’ results in long-lived memory B cells and long-lived plasma cells that
secrete high-affinity, neutralizing antibody. The precise roles played by TLRs andDCs in the germinal-center reaction and in the generation of memory
B cells and long-lived plasma cells are poorly understood. DCs and TLRs may operate at multiple levels, including TLR-mediated activation of DCs in
the T cell-rich areas; TLR triggering of B cells directly; by influencing the decision of whether an activated B cell should enter a germinal center or the
plasma foci; by regulating the processes of cell division, somatic hypermutation, and selection of high-affinity B cells within the germinal center; and
by regulating the decision as to whether to become a long-lived memory B cell or a long-lived plasma cell or return to the foci to become a short-lived
plasma cell. In addition, TLRs might continuously trigger long-lived memory B cells to maintain ‘‘serological memory’’ (Bernasconi et al., 2002).restricted, their antibody may constitute a dominant frac-
tion of serum IgM and up to half of IgAmolecules in the gut
and is often reactive to host molecules. The roles played
by such antibodies are largely unknown, although they
likely protect against infections in infancy and againstCgut flora. The role of the innate immune system in regulat-
ing B-1 B cells is poorly understood, although recent stud-
ies suggest that complement receptors CD21/CD35 are
important in the selection, activation, and expansion of
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that triggering TLRs on B-1 B cells by PAMPs in the gut
flora, in concert with BCR signaling and complement-re-
ceptor triggering, results in synergistic and persistent ac-
tivation of such cells and ‘‘natural antibody’’ production.
Programming Marginal-Zone B Cells to Rapidly Gener-
ate Neutralizing Antibodies and ‘‘Natural Memory.’’ A sub-
set of B cells that has functional similarities to the B-1 B
cells are the marginal-zone B cells, which are strategically
located in the marginal zones of the spleens. Like B-1 B
cells, they also play a dominant role in the early IgM re-
sponse to blood-borne pathogens, toxins, and viruses
that drain the spleen (Lopez-Cavalho and Kearney,
2004). The level of expression of the costimulatory mole-
cules B7.1 and B7.2 on marginal-zone B cells is higher
than on recirculating follicular B cells, suggesting a persis-
tent state of activation, like B-1 B cells. A recent study
suggests that blood-derived neutrophils and CD11clow
immature DCs are the main cells that capture and trans-
port bacteria to the spleen, provide critical survival signals
in the form of TNF superfamily members BAFF and APRIL,
and promote their differentiation into plasma cells (Lopez-
Cavalho and Kearney, 2004).
The propensity of B-1 B cells to proliferate and differen-
tiate continuously in vivo and the preactivated state of the
marginal-zone B cells might be exploited to generate per-
sistent levels of broadly reactive neutralizing IgM and IgA
antibodies reactive to pathogens such as HIV (Haynes
et al., 2005). Furthermore, it is conceivable that such strat-
egies might be used in vaccination campaigns aimed at
‘‘preprogramming’’ the repertoire of B-1 B cells and mar-
ginal-zone B cells toward pathogen specificities that are
likely to be encountered in disease-endemic areas. This
might be accomplished using conjugate prophylactic vac-
cines comprised of the appropriate TLR ligands conju-
gated with the specific antigens (e.g., HIV gp120) plus
complement and administered (orally or intravenously) pe-
riodically to target the B-1 B cells in the gut or marginal-
zone B cells and to induce persistent antibodies against
pathogens. Alternatively, the low threshold of activation
of B-1 B and marginal-zone B cells might be exploited to
induce an accelerated antibody response to pathogens
that can cause rapid disease, like Bacillus anthracis or
Ebola or Lassa viruses. Thus, learning how to optimally
trigger B-1 B cells and marginal-zone B cells in order to
rapidly elicit neutralizing antibodies against pathogens is
a critical challenge (critical challenge 3).
Programming the Development of Long-Lived Memory
B Cells and Long-Lived Plasma Cells with Innate Immunity.
The pathways described above can generate rapid IgM
and IgA antibody production but do not result in high-affin-
ity antibodies, nor do they generate immunological mem-
ory in B cells. Clearly the ability of B cells to remember
their past antigenic encounter and to generate long-lived
neutralizing antibodies is one of the hallmarks ofmost suc-
cessful vaccines. An important question is the role that an-
tigen plays in the maintenance of B cell memory. Despite
earlier reports that antigen, in the form of immune com-
plexes trapped on follicular dendritic cells, is required for858 Cell 124, 849–863, February 24, 2006 ª2006 Elsevier Inc.memory B cell turnover (Gray and Skarvall, 1988), recent
evidence suggests that memory B cells can survive for
a long period, even for several years, without seeing anti-
gen (Lam et al., 1997; Maruyama et al., 2000).
Activation of naive B cells occurs at the margins of the T
cell-rich areas and B cell follicles (McHeyzer-Williams and
McHeyzer-Williams, 2005). The activated B cells can then
(1) remain in the T cell-rich areas and differentiate into
short-lived plasma cells in areas called plasma foci (Kel-
soe, 2000; MacLennan et al., 2003; McHeyzer-Williams
andMcHeyzer-Williams, 2005) or (2) migrate into B cell fol-
licles and, with CD4 T cell help, initiate a germinal center
(GC) reaction. During the GC reaction, B cells undergo so-
matic hypermutation, resulting in the generation of high-
affinity B cells, a process known as affinity maturation
(Kelsoe, 2000; MacLennan et al., 2003; McHeyzer-
Williams and McHeyzer-Williams, 2005). Such positively
selected high-affinity B cells may migrate to the plasma
foci and become antibody-producing cells, migrate to
the bone marrow to become a long-lived plasma cell, or
differentiate into long-lived memory B cells (Ahmed and
Gray, 1996; Slifka et al., 1998). Memory B cell responses
are different from primary B cell responses in three
ways: (1) they are faster; (2) they produce more antibody,
particularly of the IgG, IgA, and IgE isotypes; and (3) they
produce higher-affinity antibody.
What role does the innate immune system play in (1)
generating short-lived plasma cells in the plasma foci, (2)
inducing robust germinal-center responses and affinity
maturation, (3) generating long-lived memory B cells, or
(4) generating long-lived plasma cells? There is consider-
able understanding of the roles played by one aspect of
the innate immune system, namely the complement sys-
tem, in regulating these processes (Fearon and Carroll,
2000). In particular, experiments using mice deficient in
complement proteins C3 or C4 or the complement recep-
tors CD21/CD25 suggest that such receptors are involved
in regulating B cell differentiation at multiple levels, includ-
ing activation of naive B cells, survival of germinal-center
B cells, selection of memory B cells, and persistence of
antibody secretion. Importantly, when mice were immu-
nized with a recombinant model antigen, hen egg lyso-
zyme (HEL), fused to murine complement protein C3d,
this fusion product was up to 10,000-fold more immuno-
genic than HEL alone (Dempsey et al., 1996). Thus, C3d
is a molecular adjuvant of innate immunity that profoundly
influences an acquired immune response.
There is, however, only limited information about the
role of TLRs, C type lectins, other PRRs, or DC subsets
in B cell differentiation. Furthermore, putative roles of in-
nate cytokines such as IL-15, IL-7, or TNF family members
(which regulate effector and memory T cell differentiation
and maintenance) are poorly understood. Recently, it has
been demonstrated that the TNF family member BAFF/
BlyS promotes the survival of naive B cells in the periphery
(Mackay et al., 2003) as well as marginal-zone B cells
(Lopez-Cavalho and Kearney, 2004). In addition, human
myeloid DCs can express BAFF, can directly activate
memory B cells in vitro, and also promote the survival of
plasmablasts derived from memory B cells (Banchereau
et al., 2000). Furthermore, recent work suggests that plas-
macytoid DCs are critical for generation of plasma cells
and anti-viral antibodies from memory B cells via a mech-
anism involving IFN-a (Jego et al., 2003).
With regards to the long-term production of antibody,
two different (although not mutually exclusive) hypotheses
have been proposed to explain the longevity of the anti-
body response in the absence of re-exposure to antigen.
First, it has been suggested that antibody levels are main-
tained by the presence of long-lived plasma cells in the
bone marrow, secreting specific antibody for extended
periods, possibly several years (Slifka et al., 1998; Manz
et al., 1997). The second hypothesis suggests that mem-
ory B cells are continually differentiating into plasma cells
in an antigen-independent manner due to bystander or
polyclonal activation (Bernasconi et al., 2002). In humans,
memory B cells constitutively express specific TLRs, in-
cluding TLR9. Naive B cells do not constitutively express
TLR9, but it can be upregulated on naive B cells when
stimulated through BCR, thus explaining the differential
sensitivity of these subsets to TLR9 triggering. Given
that neutralizing antibodies represent a critical line of de-
fense, it is very likely that the immune system has evolved
multiple mechanisms to maintain persistent levels of neu-
tralizing antibody. Clearly, several unanswered questions
remain. For example, what roles do specific subsets of
DCs and specific TLRs or PRRs play in inducing the differ-
entiation of long-livedmemory B cells and plasma cells? Is
it necessary to trigger TLRs or other PRRs directly on B
cells, as well as on DCs, in order to generate long-lived
memory B cells and plasma cells? Thus, elucidation of
mechanisms by which innate immunity regulates the gen-
eration of memory B cells and long-lived plasma cells that
secrete neutralizing antibody and home tomucosal sites is
a critical challenge (critical challenge 4).
Learning Immunology from ‘‘Good’’ Vaccines
In the past 200-odd years since Jenner, vaccination has
controlled the spread of smallpox, diphtheria, tetanus, yel-
low fever, pertussis,Haemophilus influenzae type b, polio-
myelitis, measles, mumps, and rubella. In fact, smallpox
has been eradicated, and the WHO expects polio to be
eradicated soon (Rappuoli. 2004; Plotkin, 2005). In addi-
tion, vaccines against hepatitis A, hepatitis B, varicella,
and pneumococcal and meningococcal infections have
had major impact on the spread of these diseases. De-
spite their great impact on public health, the majority of
successful vaccines have been derived empirically. For
example, yellow fever vaccine 17D (YF-17D) is considered
to be one of the most effective vaccines available and has
been administered to over 400 million people worldwide
(Pugachev et al., 2005). In many individuals, neutralizing-
antibody titers have been detected for as long as 35 years
following a single vaccination. In addition, YF-17D also
has been demonstrated to be a potent inducer of cyto-
toxic T cell responses. Despite its efficacy, its mechanismCof action is not understood. Our recent data suggest that
YF-17D activates multiple subsets of DCs by signaling
through multiple TLRs, including TLRs 2, 7, 8, and 9, re-
sulting in diverse types of adaptive immune responses
(Querec et al., 2006). One immunological consequence
of this appears to be the generation of immune diver-
sity—distinct TLRs appear to activate specific DC re-
sponses that then activate particular T cell responses.
Consistent with this, a recent study in nonhuman primates
suggests that synthetic ligands that target both TLRs 7
and 8 (and thus activate both myeloid and plasmacytoid
DCs) induce stronger and qualitatively different, antigen-
specific CD8+ T cell responses than CpG DNA, which
only targets TLR9 plasmacytoid DCs (Wille-Reece et al.,
2006). Another advantage of triggering multiple TLRs
might be to generate immune synergy. Consistent with
this, a recent report suggests that combinations of spe-
cific TLR ligands display synergistic effects in their ability
to induce IL-12p70 from DCs in vitro (Napolitani et al.,
2005).
In contrast to highly effective vaccines such as YF-17D,
it may also be advantageous to study why some vaccines
induce suboptimal immune responses. For example, the
currently licensed US anthrax vaccine approved for use
in humans (AVA) consists of filtered culture supernatants
of an attenuated strain of B. anthracis adsorbed to alum.
A similar vaccine is available in the United Kingdom.
AVA is licensed to be given in a six-dose series at 0, 2,
and 4 weeks and 6, 12, and 18 months. It is conceivable
that the striking differences in dosing requirements be-
tween YF-17D and AVA reflect, amongst other things, ma-
jor differences in the ability of the two vaccines to stimu-
late the innate immune system. Indeed, a recent study
suggests that the United Kingdom anthrax vaccine is
a poor stimulator of DC maturation and subsequent T
cell stimulation (Skowera et al., 2005). This may be ac-
counted for by a lack of TLR signals in AVA or by the pres-
ence of small amounts of lethal factor (LF), which is known
to suppress DC maturation (Agrawal et al., 2003a).
Finally, there is evidence that some vaccine vectors,
such as the vaccinia virus, with which billions of individuals
were immunized during the smallpox eradication cam-
paign in the 1970s (Crotty et al., 2003), infects DCs, (par-
adoxically) inhibits DC activation, and causes extensive
cell death, resulting in crosspresentation of cellular anti-
gen (Norbury et al., 2002). The mechanism of inhibition
of DC activation is poorly understood, although two vac-
cinia virus ORFs termed A46R and A52R, when expressed
in mammalian cells, were shown to interfere specifically
with IL-1 signal transduction. A46R partially inhibited IL-
1-mediated activation of the transcription factor NF-kB,
and A52R potently blocked IL-1-, TLR4-, and TLR3-medi-
ated NF-kB activation (Harte et al., 2003). Furthermore,
the roles played by the non-TLR viral sensors, including
RIG-1, Mda-5, MAVS, and protein kinase R, in mediating
the robust and persistent immunogenicity of such vectors
need to be ascertained. Clearly, these data suggest that
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Table 1. Some Immunological Challenges for Vaccinologists
1 Elucidation of mechanisms bywhich innate immunity regulates memory T cell generation, maintenance, andmigration to
mucosal sites
2 Elucidation of the signaling networks within DCs that induce Th2 or T regulatory responses and discovery of strategies
to relieve such regulatory networks, particularly in chronic infections and tumors
3 Learning how to optimally trigger B-1 B cells and marginal-zone B cells to rapidly elicit neutralizing antibodies
4 Elucidation of mechanisms by which innate immunity regulates the generation of memory B cells and long-lived plasma
cells that secrete neutralizing antibody and home to mucosal sites
5 Understanding the innate immune mechanisms by which the best empirical vaccines induce qualitatively diverse and
long-lasting protective immune responses
6 Development of novel vaccine delivery systems (e.g., nanotechnology) to design vaccines that recapitulate or surpass
the efficacy of our best empirical vaccinesdetermine the specific combinations of innate immune re-
ceptors and DC subsets that they activate and how this
controls specific aspects of adaptive immunity will be in-
structive in guiding the design of future vaccines. Thus,
understanding the innate immune mechanisms by which
such vaccines induce qualitatively diverse and long-last-
ing protective immune responses is a key area for further
research (critical challenge 5).
In addition, recent advances are beginning to permit
a more ‘‘systems biological’’ approach to understanding
the early innate immune signatures of such ‘‘good’’ and
‘‘bad’’ vaccines (Aderem, 2005). The information gathered
from such studies should then be used to generate the
vaccines of the future—perhaps consisting of multiple
TLR ligands that provide both immune synergy (Napolitani
et al., 2005) and immune diversity (Querec et al., 2006) in
combination with antigen plus or minus synthetic mole-
cules that might regulate signaling within DCs. Thus, the
development of novel vaccine delivery systems, perhaps
using nanotechnology, to design vaccines that recapitu-
late the efficacy of our best empirical vaccines is a critical
area for further work (critical challenge 6).
Some Critical Immunological Challenges
for Vaccinologists
The recent renaissance in innate immunity is beginning to
provide answers to fundamental questions of how the im-
mune system generates long-term T and B cell memory
and protective immunity against pathogens. A central
theme is that critical parameters in the innate immune sys-
tem, such as the nature of the DC subset or the PRR, exert
a profound influence on the strength, duration, and quality
of T and B cell responses. In this context, the precise roles
played by individual TLRs; specific combinations of TLRs;
or, indeed, the growing list of non-TLRPRRs, such as RIG-
1, Mda-5, MAVS, and PKR, in the induction of long-term T
and B cell responses andmemory is likely to be an area for
fertile exploration. A related, equally important concept is
that this renaissance in innate immunity is providing us
with a new vision to understand how our best empirically
derived vaccines work. These and the other critical chal-
lenge discussed in the present review are summarized860 Cell 124, 849–863, February 24, 2006 ª2006 Elsevier Inc.in Table 1. Clearly, the successful solution of these chal-
lenges will be of great value in the design of future vac-
cines against a multitude of emerging and reemerging
infections.
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